These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Purpuric drug eruption and alopecia induced by erlotinib. Nakamura-Wakatsuki T; Yamamoto T Dermatol Online J; 2012 May; 18(5):16. PubMed ID: 22630586 [TBL] [Abstract][Full Text] [Related]
12. Unusual eruption in association with sorafenib: a case of acquired perforating dermatosis, reactive perforating collagenosis type. Lederhandler M; Beasley JM; Brinster NK; Nagler AR Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677801 [TBL] [Abstract][Full Text] [Related]
13. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy. Campbell TM; Brown CW J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770 [TBL] [Abstract][Full Text] [Related]
18. Erlotinib-induced reactive perforating collagenosis in a case of lung adenocarcinoma. Jiang X; Song TT; Hao F Indian J Dermatol Venereol Leprol; 2021 [SEASON]; 87(4):548-551. PubMed ID: 34219432 [No Abstract] [Full Text] [Related]
19. Erlotinib-associated skin reactions - case report and proposal for classification. Zoller A; Schäd SG; Gross GE Br J Dermatol; 2006 Dec; 155(6):1293-5. PubMed ID: 17107405 [No Abstract] [Full Text] [Related]